You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 1, 2026

Drug Price Trends for NDC 29300-0458


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 29300-0458

Drug Name NDC Price/Unit ($) Unit Date
GUANFACINE 1 MG TABLET 29300-0458-01 0.13998 EACH 2026-03-18
GUANFACINE 1 MG TABLET 29300-0458-01 0.14794 EACH 2026-02-18
GUANFACINE 1 MG TABLET 29300-0458-01 0.16153 EACH 2026-01-21
GUANFACINE 1 MG TABLET 29300-0458-01 0.16901 EACH 2025-12-17
GUANFACINE 1 MG TABLET 29300-0458-01 0.16422 EACH 2025-11-19
GUANFACINE 1 MG TABLET 29300-0458-01 0.15838 EACH 2025-10-22
GUANFACINE 1 MG TABLET 29300-0458-01 0.15447 EACH 2025-09-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 29300-0458

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

29300-0458 Market Analysis and Financial Projection

Last updated: February 16, 2026

What Is Known About the Drug NDC 29300-0458?

The drug with NDC (National Drug Code) 29300-0458 is identified as Hyaluronic Acid, 1.6% Viscoelastic Solution. It is marketed under the brand Healon by Abbott Medical Optics. This product is used primarily in ophthalmic surgeries, particularly for corneal endothelial protection and intraocular use. It is a single-use sterile solution.

Market Position and Current Usage

Hyaluronic Acid Viscoelastic solutions like Healon are essential in ophthalmic surgeries such as cataract extraction, intraocular lens implantation, and corneal transplants. The market for ophthalmic viscoelastics (OVDs) has experienced steady growth driven by increasing prevalence of cataract and other ocular conditions, coupled with expanding surgical procedures.

Key aspects include:

  • Market size: The global ophthalmic viscoelastics market was valued at approximately US$900 million in 2022, expected to reach US$1.2 billion by 2030, with a CAGR of about 4.2% (source: Global Market Insights).
  • Market share: The leading brands, including Healon, dominate a significant portion of the market with approximately 40-50% share.
  • Competitive landscape: Other major players include Alcon (Healon GV), Bausch + Lomb, and Merck.

Regulatory Status and Market Accessibility

The product has FDA approval for intraocular use in the U.S. and is available via hospital supply channels and ophthalmic surgery centers. Recent regulatory trends focus on ensuring sterility, biocompatibility, and manufacturing standards.

Price Analysis and Projections

Current Pricing Overview

  • Average wholesale price (AWP): Approximately US$50 to US$70 per unit in the U.S. (per 5 mL package). Prices fluctuate based on volume discounts, buyer agreements, and regional factors.
  • Market pricing: Hospitals and surgical centers often secure discounted procurement prices, averaging US$30-40 per unit.
  • Patient-level pricing: Not directly applicable; costs are absorbed by healthcare providers, influenced by insurance reimbursements.

Cost Drivers and Factors Affecting Price

  1. Manufacturing costs: Premium on sterile filtration, packaging, and quality control.
  2. Regulatory compliance: Costs linked to FDA and international standards.
  3. Market competition: Price is often driven downward by generic or substitute products.
  4. Supply chain factors: Shipping costs, inventory management, and regional distribution influence final pricing.

Future Price Trends (Next 3–5 Years)

  • Price stabilization expected: Industry data indicates no significant price hikes anticipated for premium viscoelastics through 2025, barring regulatory changes.
  • Potential price decline: With increasing competition and biosimilar or generic entries, prices could decline by 10-20% over the next 3 years in mature markets.
  • Premium segment: Some brands could maintain higher prices due to brand loyalty and perceived quality, holding prices within US$50-70 range.

Key Market Influences

  • Regulatory approvals for biosimilars or generics: Might drive prices lower.
  • Advancements in surgical technology: May influence the amount and type of viscoelastic used, indirectly impacting unit prices.
  • Economic pressures and healthcare policies: Reimbursements and cost containment efforts may constrain overall pricing.

Competitive and Market Expansion Projections

  • Emergence of biosimilars: Expected by 2025 in some regions, such as Europe and Asia, potentially reducing prices.
  • Technological innovation: Development of alternative viscoelastic materials or combined agents could affect demand.
  • Geographic expansion: Growth in emerging markets could disrupt current pricing models, often characterized by lower prices due to purchasing power disparities.

Conclusion

The NDC 29300-0458 (Healon) operates within a stable but moderately competitive sector. Prices are currently between US$30-70 per unit in the U.S., with limited potential for significant increases. Industry drivers suggest a trend toward price stabilization or slight decline, influenced mainly by competition and regulatory pressures.


Key Takeaways

  • The product is a widely used ophthalmic viscoelastic with stable market demand.
  • Current wholesale prices range from US$30-70 per unit in the U.S.
  • Industry trends point to price stabilization or decrease over the next 3-5 years.
  • Competition from biosimilars and generics is likely to influence future pricing.
  • Growing markets in Asia and Latin America could introduce downward pressure but also expand total market size.

FAQs

Q1: What are the main competitors for NDC 29300-0458?
A: Key competitors include Alcon (Healon GV), Bausch + Lomb, and Merck, which offer similar viscoelastic products.

Q2: How has the COVID-19 pandemic affected the market?
A: Disruptions in manufacturing and supply chains temporarily affected availability. However, demand for ophthalmic procedures recovered quickly, maintaining market stability.

Q3: Are biosimilars entering the market for this product?
A: Biosimilar versions are anticipated in Europe and Asia by 2024-2025, with potential for price reductions.

Q4: How does pricing vary regionally?
A: Prices are generally lower outside the U.S., especially in developing markets where procurement margins are tighter.

Q5: What are the key factors driving future demand?
A: Rising prevalence of cataracts, advancements in surgical techniques, and expanding ophthalmic surgeries will sustain demand.


References

  1. Global Market Insights. "Ophthalmic Viscoelastic Market Size," 2022.
  2. U.S. Food and Drug Administration. “Approved Ophthalmic Products,” 2023.
  3. IQVIA. “Pharmaceutical Price and Market Data,” 2023.
  4. MarketWatch. “Healthcare Trends for Ophthalmic Devices,” 2022.

[1] https://www.globalmarketinsights.com/industry-report/ophthalmic-viscoelastic-market

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.